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PROPOSITION

61

STATE PRESCRIPTION DRUG PURCHASES. PRICING STANDARDS.
INITIATIVE STATUTE.

OFFICIAL TITLE AND SUMMARY
• Prohibits state agencies from buying any
prescription drug from a drug manufacturer
at any price over the lowest price paid for the
same drug by the United States Department of
Veterans Affairs, except as may be required by
federal law.
• Applies to any program where the state agency
is the ultimate payer for a prescription drug,
even if the state agency does not itself buy the
drug.
• Exempts purchases of prescription drugs

PREPARED BY THE ATTORNEY GENERAL

under managed care programs funded through
Medi-Cal.

SUMMARY OF LEGISLATIVE ANALYST’S ESTIMATE OF NET
STATE AND LOCAL GOVERNMENT FISCAL IMPACT:
• Potential for state savings of an unknown
amount depending on (1) how the measure’s
implementation challenges are addressed
and (2) the responses of drug manufacturers
regarding the provision and pricing of their
drugs.

ANALYSIS BY THE LEGISLATIVE ANALYST
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BACKGROUND

purchased by the pharmacies and dispensed to
individuals enrolled in certain state programs.

The State Payments for Prescription Drugs

Annual State Drug Expenditures Totaled Almost
$3.8 Billion in 2014–15. As shown in Figure 1, the
state spent almost $3.8 billion on prescription
drugs in 2014–15 under a variety of state
programs. State funds pay for roughly half of
overall state prescription drug spending, and the
remainder is paid with federal and other nonstate
revenues.

State Pays for Prescription Drugs Under Many
Different State Programs. Typically, the state
pays for prescription drugs under programs that
provide health care or health insurance to certain
state populations. For example, the state pays
for prescription drugs through the health care
coverage it provides to the state’s low-income
residents through the MediCal program and to current
and retired state employees.
The state also provides and
pays for the health care of
prison inmates, including
their prescription drug
costs.
State Pays for Prescription
Drugs in a Variety of Ways.
In some cases, the state
purchases prescription
drugs directly from drug
manufacturers. In other
cases, the state pays
for prescription drugs
even though it is not
the direct purchaser of
them. For example, the
state reimburses retail
pharmacies for the cost
of prescription drugs
72 | Title and Summary / Analysis
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Prescription Drug Pricing in General
Prices Actually Paid Often Differ From the Drugs’
“List Prices.” Prescription drugs sold in the United
States have list prices that are similar to the
manufacturer’s suggested retail price (MSRP) for
automobiles. Purchasers of the drugs typically
negotiate the prices and often receive discounts.
As a result, the final price paid for a prescription
drug is typically lower than its list price.
Different Payers Often Pay Different Prices for
the Same Prescription Drug. Often there is no
single price paid by all payers for a particular
prescription drug. Instead, different payers may
regularly pay different prices for the same drug,
which reflects the results of negotiations between
the drugs’ buyers and sellers. For example, two
different insurance companies may pay different
prices for the same drug, as may two separate
state agencies such as the California Department
of Health Care Services (DHCS) and the California
Department of Public Health.
Prices Paid for Prescription Drugs Are Often Subject
to Confidentiality Agreements. Prescription drug
purchase agreements often contain confidentiality
clauses that are intended to prohibit public
disclosure of the agreed prices. As a result, the
prescription drug prices paid by a particular
entity, including a government agency, may be
unavailable to the public.

State Prescription Drug Pricing
State Strategies to Reduce Prescription Drug
Prices. California state agencies pursue a
variety of strategies to reduce the prices they
pay for prescription drugs, which typically
involve negotiating with drug manufacturers
and wholesalers. The particular strategies vary
depending on program structure and the manner
in which the state programs pay for drugs. For
example, multiple California state departments
jointly negotiate drug prices with manufacturers.
By negotiating as a single, larger entity, the
participating state departments are able to obtain
lower drug prices. Another state strategy is to
negotiate discounts from drug manufacturers in
exchange for reducing the overall administrative
burden on doctors prescribing these
manufacturers’ drugs.
For the full text of Proposition 61, see page 154.
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United States Department of Veterans Affairs (VA)
Prescription Drug Pricing
VA Provides Health Care to Veterans. The
VA provides comprehensive health care to
approximately nine million veterans nationwide.
In doing so, the VA generally purchases the
prescription drugs that it makes available to VA
health care beneficiaries.
Programs to Reduce Federal Prescription Drug
Expenditures. The federal government has
established discount programs that place upper
limits on the prices paid for prescription drugs by
selected federal payers, including the VA. These
programs generally result in lower prices than
those available to private payers.
VA Obtains Additional Discounts From Drug
Manufacturers or Sellers. On top of the federal
discount programs described above, the VA
often negotiates additional discounts from drug
manufacturers or sellers that lower its prices
below what other federal departments pay.
Manufacturers or sellers provide these discounts
in return for their drugs being made readily
available to VA patients.
VA Publishes Some of Its Prescription Drug Pricing
Information. The VA maintains a public database
that lists the prices paid by the VA for most of the
prescription drugs it purchases. According to the
VA, however, the database may not display the
lowest prices paid for some of the drugs for which
the VA obtains additional negotiated discounts.
The VA may not publish this pricing information
in the database due to confidentiality clauses
that are included in certain drugs’ purchase
agreements and are intended to prohibit public
disclosure of the negotiated prices.
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PROPOSAL
Measure Sets an Upper Limit on Amount State Can
Pay for Prescription Drugs. This measure generally
prohibits state agencies from paying more for a
prescription drug than the lowest price paid by
the VA for the same drug after all discounts are
factored in for both California state agencies and
the VA.
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ANALYSIS BY THE LEGISLATIVE ANALYST
Measure Applies Whenever the State Is the Payer of
Prescription Drugs. The measure’s upper limit on
state prescription drug prices applies regardless
of how the state pays for the prescription drugs. It
applies, for example, whether the state purchases
prescription drugs directly from a manufacturer or
instead reimburses pharmacies for the drugs they
provide to enrollees of state programs.
Measure Exempts a Portion of the State’s Largest
Health Care Program From Its Drug Pricing
Requirements. The state’s Medi-Cal program offers
comprehensive health coverage to the state’s lowincome residents. The state operates Medi-Cal
under two distinct service delivery systems: the
fee-for-service system (which serves approximately
25 percent of Medi-Cal enrollees) and the
managed care system (which serves approximately
75 percent of enrollees). While the measure
applies to the fee-for-service system, it exempts
the managed care system from its drug pricing
requirements described above.
DHCS Required to Verify That State Agencies
Are Complying With Measure’s Drug Pricing
Requirements. The measure requires DHCS to
verify that state agencies are paying the same
or less than the lowest price paid by the VA on a
drug-by-drug basis.
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FISCAL EFFECTS
By prohibiting the state from paying more for
a prescription drug than the lowest price paid
by the VA, there is the potential for the state to
realize reductions in its drug costs. There are,
however, major uncertainties concerning (1) the
implementation of the measure’s lowest-cost
requirement and (2) how drug manufacturers
would respond in the market. We discuss these
concerns below.

Potential Implementation Challenges
Create Fiscal Uncertainty
Some VA Drug Pricing Information May Not Be
Publicly Accessible. The measure generally
requires that the prescription drug prices paid
by the state not exceed the lowest prices paid by
the VA on a drug-by-drug basis. As mentioned
above, the VA’s public database information on
74 | Title and Summary / Analysis
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the prices of the prescription drugs it purchases
does not always identify the lowest prices the VA
pays. This is because, at least for some drugs,
the VA has negotiated a lower price than that
shown in the public database and is keeping that
pricing information confidential. It is uncertain
whether the VA could be nonetheless required
to disclose these lower prices to an entity—such
as DHCS—requesting such information under
a federal Freedom of Information Act (FOIA)
request. A FOIA exemption covering trade secrets
and financial information may apply to prevent
the VA from having to disclose these currently
confidential prices to the state.
Confidentiality of VA Drug Prices Could Compromise
the State’s Ability to Implement the Measure. If
the VA is legally allowed to keep some of its
prescription drug pricing information confidential,
DHCS would be unable to assess in all cases
whether state agencies are paying less than or
equal to the lowest price paid by the VA for the
same drug. This would limit the state’s ability to
implement the measure as it is written. However,
to address challenges in implementing laws,
courts sometimes grant state agencies latitude to
implement laws to the degree that is practicable
as long as implementation is consistent with the
laws’ intent. For example, courts might allow the
state to pay for drugs at a price not exceeding the
lowest known price paid by the VA, rather than
the actual lowest price, to allow the measure to be
implemented.
Potential Confidentiality of Lowest VA Drug Prices
Reduces but Does Not Eliminate Potential State
Savings. The potential confidentiality of at
least some of the lowest VA prices reduces but
does not eliminate the measure’s potential to
generate savings related to state prescription
drug spending. Though pricing information may
be unavailable for some of the VA’s lowest-priced
prescription drugs, publicly available VA drug
prices have historically been lower than the
prices paid by some California state agencies for
some drugs. To the extent that the VA’s publicly
available drug prices for particular drugs are lower
than those paid by California state agencies and
manufacturers choose to offer these prices to the
state, the measure would help the state achieve
prescription drug-related savings.
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ANALYSIS BY THE LEGISLATIVE ANALYST

Potential Drug Manufacturer Responses
Limit Potential Savings
Drug Manufacturer Responses Under Measure
Could Significantly Affect Fiscal Impact. In order to
maintain similar levels of profits on their products,
drug manufacturers would likely take actions that
mitigate the impact of the measure. A key reason
why drug manufacturers might take actions in
response to the measure relates to how federal law
regulates state Medicaid programs’ prescription
drug prices. (Medi-Cal is California’s Medicaid
program.) Federal law entitles all state Medicaid
programs to the lowest prescription drug prices
available to most public and private payers in the
United States (excluding certain payers, such
as the VA). If certain California state agencies
receive VA prices, as the measure intends, this
would set new prescription drug price limits at VA
prices for all state Medicaid programs. As a result,
the measure could extend the VA’s favorable drug
prices to health programs serving tens of millions
of additional people nationwide, placing added
pressure on drug manufacturers to take actions to
protect their profits under the measure.
Below are two possible manufacturer responses.
(We note that manufacturers might ultimately
pursue both strategies, while at the same time
offering some drugs at favorable VA prices.)
• Drug Manufacturers Might Raise VA Drug
Prices. Knowing that the measure makes
VA prices the upper limit for what the
state can pay, drug manufacturers might
choose to raise VA drug prices. This would
allow drug manufacturers to continue to
offer prescription drugs to state agencies
while minimizing any reductions to their
profits. Should manufacturers respond in
this manner, potential savings related to
state prescription drug spending would be
reduced.
• Drug Manufacturers Might Decline to Offer
Lowest VA Prices to the State for Some Drugs.
The measure places no requirement on
drug manufacturers to offer prescription
drugs to the state at the lowest VA prices.
Rather, the measure restricts actions that
the state can take (namely, prohibiting the
For the full text of Proposition 61, see page 154.
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state from paying more than the lowest VA
prices for prescription drugs). Therefore, if
manufacturers decide it is in their interest
not to extend the VA’s favorable pricing to
California state agencies (for example, to
avoid consequences such as those described
above), drug manufacturers could decline
to offer the state some drugs purchased by
the VA. In such cases, these drugs would be
unavailable to most state payers. Instead,
the state would be limited to paying for
drugs that either the VA does not purchase
or drugs that manufacturers will offer at
the lowest VA prices. (However, to comply
with federal law, Medi-Cal might have to
disregard the measure’s price limits and pay
for prescription drugs regardless of whether
manufacturers offer their drugs at or below
VA prices.) This manufacturer response could
reduce potential state savings under the
measure since it might limit the drugs the
state can pay for to those that, while meeting
the measure’s price requirements, are
actually more expensive than those currently
paid for by the state.

Summary of Overall Fiscal Effect
As discussed above, if adopted, the measure
could generate annual state savings. However,
the amount of any savings is highly uncertain
as it would depend on (1) how the measure’s
implementation challenges are addressed and
(2) the uncertain market responses of drug
manufacturers to the measure. As a result, the
fiscal impact of this measure on the state is
unknown. It could range from relatively little
effect to significant annual savings. For example,
if the measure lowered total state prescription
drug spending by even a few percent, it would
result in state savings in the high tens of millions
of dollars annually.

61

Visit http://www.sos.ca.gov/measure-contributions
for a list of committees primarily formed to support
or oppose this measure. Visit http://www.fppc.ca.gov/
transparency/top‑contributors/nov-16-gen-v2.html
to access the committee’s top 10 contributors.
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★ ARGUMENT IN FAVOR OF PROPOSITION 61 ★
Drug companies making enormous profits from people’s
illnesses and misery isn’t just a moral issue. Skyrocketing
prescription drug prices are a matter of life and death.
More Americans die of hepatitis C than from all other
infectious diseases—EVEN THOUGH THERE’S A CURE.
One reason? The drug company that controls it charges
more than $1,000 per pill, out of most patients’ reach.
That’s not the only outrageous example of drug-company
price-gouging:
• The price of a common infection-ﬁghting pill was
raised overnight from $13.50 to $750—nearly a 5000%
increase. • The average annual cost of widely-used
specialty drugs is estimated at $53,000 —greater than
the nation’s median household income ($52,000) and
almost 3 1/2 times larger than average annual Social
Security beneﬁts of $15,000. • One cancer drug costs
$300,000 a year.
The drug companies put profits over people, returns
for stockholders over cures for patients. What good are
miraculous, life-saving medications, if they’re priced so
high patients can’t afford them—and thousands are dying
as a result?
Proposition 61, The California Drug Price Relief Act,
fights back against the drug companies’ price-gouging.
And it is expected to save lives. Here’s how it would work:
The Act would require the State of California to negotiate
with drug companies for prices that are no more than the
amounts paid for the same drugs by the U.S. Dept. of
Veterans Affairs (DVA).
Why the Dept. of Veterans Affairs? Because unlike
Medicare, the DVA negotiates for drug prices, and pays
on average 20–24% less for medications than other
government agencies, up to 40% less than Medicare
Part D. The Drug Price Relief Act empowers the State
of California, as the healthcare buyer for millions of
Californians, to negotiate the same or even better deals for
taxpayers, which could save billions in healthcare costs.
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Drug companies are planning to spend $100 million to
fight this measure because they know it would cause
downward pressure on ALL drug prices—and cut into their
excessive profits.
Don’t just take our word for it, a publication for drug
executives called Prop. 61 “GROUND ZERO” in the
national fight for lower drug prices, warning:
“If the voters of California approve this
proposition . . . [it] would no doubt cause an immediate
demand for the same VA discount rate to be made
available to other states, the federal government, and
likely private [health plan] entities, as well. IN SHORT [IT]
WOULD BE A PRICING DISASTER FOR THE ENTIRE U.S.
DRUG INDUSTRY.”
But a “pricing disaster” for drug companies would equal
price relief for hard-pressed consumers.
Prop. 61 is strongly supported by the 86,000-member
California Nurses Association—the largest healthcareprovider organization in the state; AARP, the largest
retirees’ group in California, with 3.3 million members;
the Urban League; the Campaign for a Healthy California,
including many labor unions; Progressive Democrats
of America; Sen. Bernie Sanders; former U.S. Labor
Secretary Robert Reich; and many others.
JOIN US IN FIGHTING AGAINST HIGH DRUG
PRICES AND DRUG COMPANY GREED. VOTE YES
ON PROPOSITION 61. For more information, go to
www.StopPharmaGreed.com.
ZENEI CORTEZ, RN, Co-President
California Nurses Association/National Nurses Organizing
Committee
NANCY McPHERSON, State Director
AARP California
SENATOR ART TORRES,(Ret.), Chair
California Democratic Party (1996–2009)

★ REBUTTAL TO ARGUMENT IN FAVOR OF PROPOSITION 61 ★
Leading experts have rejected proponents’ claim that Prop.
61 would somehow reduce drug prices. In fact, EXPERTS
WARN PROP. 61 WILL INCREASE DRUG PRICES.
The California Medical Association, the state’s foremost
medical organization representing 41,000 doctors, says:
“While California’s physicians are profoundly concerned
about the affordability of prescription drugs, we evaluated
this measure and have concluded it is deeply flawed
and unworkable. We believe the measure would likely
increase—not lower—state prescription drug costs.”
The highly-respected, independent California State
Legislative Analyst says Prop. 61 “could raise (state)
spending on prescription drugs.”
The California Taxpayers Association opposes Prop. 61
because it would impose new bureaucracy and red tape, and
cause countless lawsuits—COSTING TAXPAYERS MILLIONS.
The Veterans of Foreign Wars (VFW), Department of
California urges NO on 61 because it could jeopardize
special discounts given to the U.S. Department of Veterans
Affairs and INCREASE DRUG PRICES FOR VETERANS.
Who’s behind this measure?
Prop. 61 was written by Michael Weinstein, president of
76 | Arguments

an organization that brings in $1 billion annually selling
prescription drugs and operating HMOs. His group is
spending millions to fund the campaign. But he exempted
his own organization from its drug pricing provisions. He
shouldn’t ask Californians to approve a flawed initiative he
isn’t willing to comply with himself.
Prop. 61 is OPPOSED BY MORE THAN 100 CALIFORNIA
ORGANIZATIONS, including:
• Vietnam Veterans of America, California State Council
• California Taxpayers Association • Veterans of Foreign
Wars (VFW), Dept. of California • California NAACP
• American Congress of Obstetricians and Gynecologists
(ACOG)—District IX/CA • California Medical Association
Prop. 61 is deeply flawed and costly. Vote NO.
www.NoProp61.com
STEVE MACKEY, President
Vietnam Veterans of America, California State Council
WILLIAM M. REMAK, Chairman
California Hepatitis C Task Force
ALICE A. HUFFMAN, President
California NAACP

Arguments printed on this page are the opinions of the authors, and have not been checked for accuracy by any official agency.
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★ ARGUMENT AGAINST PROPOSITION 61 ★
Proposition 61 is a deeply flawed and costly scheme that
is not what it seems.
Prop. 61 was written and is being promoted by Michael
Weinstein, the controversial president of an organization
that brought in more than $1 billion selling prescription
drugs and HMO policies. Suspiciously, he exempted his
own HMO from having to comply with the measure he
wrote and is promoting.
• The Veterans of Foreign Wars, Department of California
warns Prop. 61 would harm veterans. • The California
Medical Association, representing 41,000 doctors, warns
Prop. 61 would reduce patient access to medicines. • The
California Taxpayers Association warns Prop. 61 would
impose new bureaucracy, red tape and lawsuits—costing
taxpayers millions.
PROP. 61 DOES NOT APPLY TO 88% OF CALIFORNIANS.
BUT IT NEGATIVELY IMPACTS ALL CALIFORNIANS

The proposition only covers an arbitrary group of patients
in certain state government programs, including some
government employees and state prisoners. More than
88% of Californians are excluded. More than 10 million
Medi-Cal low-income patients, 20 million Californians
with private health insurance and Medicare, and millions
of others—ALL EXCLUDED.
PROP. 61 COULD INCREASE PRESCRIPTION DRUG
COSTS FOR VETERANS

The US Department of Veterans Affairs receives special
discounts on prescription drugs for veterans. This
measure could result in eliminating these discounts and
increasing prescription drug prices for veterans. That’s
why the measure is opposed by more than a dozen
veteran groups, including:
• Veterans of Foreign Wars, Department of California
• Vietnam Veterans of America, California State Council
• American Legion, Department of California
• AMVETS, Department of California
DOCTORS AND PATIENT ADVOCATES SAY PROP. 61
WOULD DISRUPT ACCESS TO NEEDED MEDICINES

Prop. 61 would result in a new bureaucratic prior approval process

that would interfere with patient access to needed medicines.
Leading health groups oppose Prop. 61, including:
• California Medical Association • American Congress of
Obstetricians and Gynecologists (ACOG)—District IX/CA
• Ovarian Cancer Coalition of Greater California
PROP. 61 WOULD LIKELY INCREASE STATE
PRESCRIPTION DRUG COSTS

Prop. 61 would result in the elimination of drug discounts
the state currently receives—increasing state prescription
costs by tens of millions annually. The state’s nonpartisan
Legislative Analyst says the measure could raise state
spending on many prescription drugs.
INCREASED BUREAUCRACY, RED TAPE AND HIGHER
TAXPAYER COSTS

The California Taxpayers Association opposes Prop. 61.
The measure is completely vague on how it would be
implemented. Passage of this measure would result in more
government bureaucracy, red tape and lawsuits as state
agencies struggle to implement it—costing taxpayers millions.
PROMOTER WROTE IN SPECIAL PROVISIONS FOR HIS
OWN ORGANIZATION

The proponent exempted his billion dollar operation and wrote
in provisions giving him a special right to engage in lawsuits
regarding this measure. This provision requires California
taxpayers to pay his lawyers—a virtual blank check.
Proposition 61 is yet another example of a misleading and
costly ballot measure. It would hurt veterans; jeopardize
patient access to needed medicines; increase state
prescription costs; and add more bureaucracy, red tape
and lawsuits—costing taxpayers millions.
JOIN VETERANS, DOCTORS, PATIENT ADVOCATES,
TAXPAYER GROUPS: NO on 61.

www.NoProp61.com
DALE SMITH, Commander
Veterans of Foreign Wars, Department of California
RANDY MUNOZ, Vice Chair, Latino Diabetes Association
GAIL NICKERSON, President
California Association of Rural Health Clinics
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★ REBUTTAL TO ARGUMENT AGAINST PROPOSITION 61 ★
The drug companies want you to believe they’re opposing
Prop. 61 because it wouldn’t cover every drug purchase
in California. That’s as laughable as the NRA saying it
opposes an assault-weapons ban because it doesn’t cover
enough different kinds of guns.
THE DRUG COMPANIES ARE ONLY CONCERNED
ABOUT MAINTAINING THEIR EXORBITANT PRICES AND
PROFITS, PURE AND SIMPLE!
Don’t be fooled by their expected $100-million campaign of
distortion and mistruths. Voting against 61 only allows the
drug companies to continue ripping off you and your family.
Despite what they’re telling voters, there’s a reason the No
on Prop. 61 campaign is FUNDED ALMOST ENTIRELY
BY OUT-OF-STATE DRUG COMPANIES. Here’s what
drugmakers are telling themselves, in publications like
Pharmaceutical Executive:
“It’s pretty clear that if this California pricing proposition
passes, ALL HELL MAY BREAK LOOSE FOR THE AMERICAN
PHARMACEUTICAL INDUSTRY . . . It would shake the
rafters of every single public state drug program in the nation,
as well as the federal Medicaid and Medicare programs.”

Drug companies are also unpatriotically threatening to raise
drug prices for veterans, BUT THAT’S ANOTHER EMPTY
THREAT. Federal law REQUIRES discounts for the Dept.
of Veterans Affairs, drug companies aren’t selling reducedprice drugs to veterans out of the goodness of their hearts.
Support Prop. 61 along with:
• California Nurses Association • AARP California • The
Urban League • AIDS Healthcare Foundation • VoteVets
Action Fund • Association of Asian Paciﬁc Community
Health Organizations • Progressive Democrats of America
ONLY PROPOSITION 61 ALLOWS ORDINARY CITIZENS
TO FIGHT BACK AGAINST DRUG COMPANY POWER
AND GREED. www.StopPharmaGreed.com.
OTTO O. YANG, M.D., Scientific Director
AIDS Healthcare Foundation
CAPTAIN SHAWN TERRIS,(Ret.), Chair
California Democratic Party Veterans Caucus
NOLAN V. ROLLINS, President
Los Angeles Urban League/California Association of
Urban Leagues

Arguments printed on this page are the opinions of the authors, and have not been checked for accuracy by any official agency.
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(p) “Person” means any individual, partnership, firm,
association, corporation, limited liability company, or other
legal entity.
(q) “Sexually Transmitted Infection” or “STI” means any
infection or disease spread by sexual intercourse,
including, but not limited to, HIV/AIDS, gonorrhea,
syphilis, chlamydia, hepatitis, trichomoniasis, genital
human papillomavirus infection (HPV), and genital herpes.
SEC. 5. Liberal Construction.
This Act is an exercise of the public power of the people of
the State of California for the protection of their health,
safety, and welfare, and shall be liberally construed to
effectuate its purposes.
SEC. 6. Conflicting Measures.
This Act is intended to be comprehensive. It is the intent
of the people of the State of California that in the event
this Act and one or more measures relating to the same
subject shall appear on the same statewide ballot, the
provisions of the other measure or measures shall be
deemed to be in conflict with this Act. In the event that
this Act receives a greater number of affirmative votes, the
provisions of this Act shall prevail in their entirety, and all
provisions of the other measure or measures shall be null
and void.
SEC. 7. Proponent Accountability.
The people of the State of California hereby declare that
the proponent of this Act should be held civilly liable in
the event this Act is struck down, after passage, in whole
or in part, by a court for being constitutionally or statutorily
impermissible. Such a constitutionally or statutorily
impermissible initiative is a misuse of taxpayer funds and
electoral resources and the Act’s proponent, as the drafter
of the Act, must be held accountable for such an
occurrence.
In the event this Act, after passage, is struck down in
court, in whole or in part, as unconstitutional or statutorily
invalid, and all avenues for appealing and overturning the
court decision have been exhausted, the proponent shall
pay a civil penalty of $10,000 to the General Fund of the
State of California for failure to draft a wholly constitutionally
or statutorily permissible initiative law. No party or entity
may waive this civil penalty.
SEC. 8. Amendment and Repeal.
This Act may be amended to further its purposes by statute
passed by a two-thirds (2/3) vote of the Legislature and
signed by the Governor.
SEC. 9. Severablility.
If any provision of this Act, or part thereof, or the
applicability of any provision or part to any person or
circumstances, is for any reason held to be invalid or
unconstitutional, the remaining provisions and parts shall
not be affected, but shall remain in full force and effect,
and to this end the provisions and parts of this Act are
severable. The voters hereby declare that this Act, and
each portion and part, would have been adopted
irrespective of whether any one or more provisions or parts
are found to be invalid or unconstitutional.
SEC. 10. Legal Defense.
The people of the State of California desire that the Act, if
approved by the voters, and thereafter challenged in court,
be defended by the State of California. The people of the
State of California, by enacting this Act, hereby declare
that the proponent of this Act has a direct and personal
154 | Text of Proposed Laws
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stake in defending this Act from constitutional or statutory
challenges to the Act’s validity. In the event the Attorney
General fails to defend this Act; or the Attorney General
fails to appeal an adverse judgment against the
constitutionality or statutory permissibility of this Act, in
whole or in part, in any court, the Act’s proponent shall be
entitled to assert his direct and personal stake by defending
the Act’s validity in any court and shall be empowered by
the citizens through this Act to act as an agent of the
citizens of the State of California subject to the following
conditions: (1) the proponent shall not be considered an
“at-will” employee of the State of California, but the
Legislature shall have the authority to remove the proponent
from his agency role by a majority vote of each house of the
Legislature when “good cause” exists to do so, as that term
is defined by California case law; (2) the proponent shall
take the Oath of Office under Section 3 of Article XX of the
California Constitution, as an employee of the State of
California; (3) the proponent shall be subject to all
fiduciary, ethical, and legal duties prescribed by law; and
(4) the proponent shall be indemnified by the State of
California for only reasonable expenses and other losses
incurred by the proponent, as agent, in defending the
validity of the challenged Act. The rate of indemnification
shall be no more than the amount it would cost the State
to perform the defense itself.
SEC. 11. Effective Date.
Except as otherwise provided herein, this Act shall become
effective the day after its approval by the voters.

PROPOSITION 61
This initiative measure is submitted to the people in
accordance with the provisions of Section 8 of Article II of
the California Constitution.
This initiative measure adds a section to the Welfare and
Institutions Code; therefore, new provisions proposed to be
added are printed in italic type to indicate that they are
new.

PROPOSED LAW
The California Drug Price Relief Act
The people of the State of California do hereby ordain as
follows:
SECTION 1. Title.
This Act shall be known, and may be cited, as “The
California Drug Price Relief Act” (the “Act”).
SEC. 2. Findings and Declarations.
The people of the State of California hereby find and
declare all of the following:
(a) Prescription drug costs have been, and continue to be,
one of the greatest drivers of rising health care costs in
California.
(b) Nationally, prescription drug spending increased more
than 800 percent between 1990 and 2013, making it one
of the fastest growing segments of health care.
(c) Spending on specialty medications, such as those
used to treat HIV/AIDS, Hepatitis C, and cancer, are rising
faster than other types of medications. In 2014 alone,
total spending on specialty medications increased by more
than 23 percent.
(d) The pharmaceutical industry’s practice of charging
inflated drug prices has resulted in pharmaceutical
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company profits exceeding those of even the oil and
investment banking industries.
(e) Inflated drug pricing has led to drug companies
lavishing excessive pay on their executives.
(f) Excessively priced drugs continue to be an unnecessary
burden on California taxpayers that ultimately results in
cuts to health care services and providers for people in
need.
(g) Although California has engaged in efforts to reduce
prescription drug costs through rebates, drug manufacturers
are still able to charge the state more than other government
payers for the same medications, resulting in a dramatic
imbalance that must be rectified.
(h) If California is able to pay the same prices for
prescription drugs as the amounts paid by the United
States Department of Veterans Affairs, it would result in
significant savings to California and its taxpayers. This Act
is necessary and appropriate to address these public
concerns.
SEC. 3. Purposes and Intent.
The people of the State of California hereby declare the
following purposes and intent in enacting this Act:
(a) To enable the State of California to pay the same prices
for prescription drugs as the prices paid by the United
States Department of Veterans Affairs, thus rectifying the
imbalance among government payers.
(b) To enable significant cost savings to California and its
taxpayers for prescription drugs, thus helping to stem the
tide of rising health care costs in California.
(c) To provide for the Act’s proper legal defense should it
be adopted and thereafter challenged in court.
SEC. 4. The California Drug Price Relief Act shall be
codified by adding Section 14105.32 to the Welfare and
Institutions Code, to read:
14105.32. Drug Pricing.
(a) Notwithstanding any other provision of law and insofar
as may be permissible under federal law, neither the State
of California, nor any state administrative agency or other
state entity, including, but not limited to, the State
Department of Health Care Services, shall enter into any
agreement with the manufacturer of any drug for the
purchase of a prescribed drug unless the net cost of the
drug, inclusive of cash discounts, free goods, volume
discounts, rebates, or any other discounts or credits, as
determined by the State Department of Health Care
Services, is the same as or less than the lowest price paid
for the same drug by the United States Department of
Veterans Affairs.
(b) The price ceiling described in subdivision (a) also shall
apply to all programs where the State of California or any
state administrative agency or other state entity is the
ultimate payer for the drug, even if it did not purchase the
drug directly. This includes, but is not limited to,
California’s Medi-Cal fee-for-service outpatient drug
program and California’s AIDS Drug Assistance Program.
In addition to agreements for any cash discounts, free
goods, volume discounts, rebates, or any other discounts
or credits already in place for these programs, the
responsible state agency shall enter into additional
agreements with drug manufacturers for further price
reductions so that the net cost of the drug, as determined
by the State Department of Health Care Services, is the
same as or less than the lowest price paid for the same
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drug by the United States Department of Veterans Affairs.
The requirements of this section shall not be applicable to
drugs purchased or procured, or rates developed, pursuant
to or under any Medi-Cal managed care program.
(c) It is the intent of the people of the State of California
that the State of California, and all state agencies and
other state entities that enter into one or more agreements
with the manufacturer of any drug for the purchase of
prescribed drugs, shall implement this section in a timely
manner, and to that end the State of California and all
such state agencies and other state entities are required to
implement and comply with this law no later than July 1,
2017.
(d) The State of California, and each and every state
administrative agency or other state entity, may adopt rules
and regulations to implement the provisions of this section,
and may seek any waivers of federal law, rule, and
regulation necessary to implement the provisions of this
section.
SEC. 5. Liberal Construction.
This Act is an exercise of the public power of the people of
the State of California for the protection of their health,
safety, and welfare, and shall be liberally construed to
effectuate its purposes.
SEC. 6. Conflicting Measures.
This Act is intended to be comprehensive. It is the intent
of the people of the State of California that in the event
this Act and one or more measures relating to the same
subject shall appear on the same statewide ballot, the
provisions of the other measure or measures shall be
deemed to be in conflict with this Act. In the event that
this Act receives a greater number of affirmative votes, the
provisions of this Act shall prevail in their entirety, and all
provisions of the other measure or measures shall be null
and void.
SEC. 7. Proponent Accountability.
The people of the State of California hereby declare that
the proponent of this Act should be held civilly liable in the
event this Act is struck down, after passage, in whole or in
part, by a court of law for being constitutionally or statutorily
impermissible. Such a constitutionally or statutorily
impermissible initiative is a misuse of taxpayer funds and
electoral resources and the Act’s proponent, as drafter of
the Act, must be held accountable for such an occurrence.
In the event this Act, after passage, is struck down in a
court of law, in whole or in part, as unconstitutional or
statutorily invalid, and all avenues for appeal have been
exhausted, the proponent shall pay a civil penalty of
$10,000 to the General Fund of the State of California for
failure to draft and sponsor a wholly constitutionally or
statutorily permissible initiative law but shall have no other
liability to any person or entity with respect to, related to,
or arising from the Act. No party or entity may waive this
civil penalty.
SEC. 8. Amendment and Repeal.
This Act may be amended to further its purposes by statute
passed by a two-thirds vote of the Legislature and signed
by the Governor.
SEC. 9. Severability.
If any provision of this Act, or part thereof, or the
applicability of any provision or part to any person or
circumstances, is for any reason held to be invalid or
unconstitutional, the remaining provisions and parts shall
Text of Proposed Laws

| 155

61

TEXT OF PROPOSED LAWS

61

not be affected, but shall remain in full force and effect,
and to this end the provisions and parts of this Act are
severable. The voters hereby declare that this Act, and
each portion and part, would have been adopted irrespective
of whether any one or more provisions or parts are found to
be invalid or unconstitutional.
SEC. 10. Legal Defense.
The people of the State of California desire that the Act, if
approved by the voters, and thereafter challenged in court,
be defended by the State of California. The people of the
State of California, by enacting this Act, hereby declare
that the proponent of this Act has a direct and personal
stake in defending this Act from constitutional or statutory
challenges to the Act’s validity. In the event the Attorney
General fails to defend this Act, or the Attorney General
fails to appeal an adverse judgment against the
constitutionality or statutory permissibility of this Act, in
whole or in part, in any court of law, the Act’s proponent
shall be entitled to assert its direct and personal stake by
defending the Act’s validity in any court of law and shall be
empowered by the citizens through this Act to act as agent
of the citizens of the State of California subject to the
following conditions: (1) the proponent shall not be
considered an “at-will” employee of the State of California,
but the Legislature shall have the authority to remove the
proponent from their agency role by a majority vote of each
house of the Legislature when “good cause” exists to do
so, as that term is defined by California case law; (2) the
proponent shall take the Oath of Office under Section 3 of
Article XX of the California Constitution as an employee of
the State of California; (3) the proponent shall be subject
to all fiduciary, ethical, and legal duties prescribed by law;
and (4) the proponent shall be indemnified by the State of
California for only reasonable expenses and other losses
incurred by the proponent, as agent, in defending the
validity of the challenged Act. The rate of indemnification
shall be no more than the amount it would cost the state
to perform the defense itself.
SEC. 11. Effective Date.
Except as otherwise provided herein, this Act shall become
effective the day after its approval by the voters.

PROPOSITION 62
This initiative measure is submitted to the people in
accordance with the provisions of Section 8 of Article II of
the California Constitution.
This initiative measure amends and repeals sections of the
Penal Code; therefore, existing provisions proposed to be
deleted are printed in strikeout type and new provisions
proposed to be added are printed in italic type to indicate
that they are new.
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The Justice That Works Act of 2016
SECTION 1. Title.
This initiative shall be known and may be cited as “The
Justice That Works Act of 2016.”
SEC. 2. Findings and Declarations.
The people of the State of California do hereby find and
declare all of the following:
1. Violent killers convicted of first degree murder must be
separated from society and severely punished.
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2. Under current law, California sentences many criminals
to death who commit first degree murder, but the state
rarely carries out executions. Instead, the state spends
millions of taxpayer dollars providing lawyers for death row
inmates, only to see the murderers it has sentenced to
death by execution die of old age in prison.
3. Since 1978, California has spent more than $4 billion
on a death penalty system that has sentenced nearly one
thousand criminals to death by execution but has executed
only 13 people. Even though there are over 700 inmates
now on death row, California has not executed anyone in
almost eleven years.
4. Violent murderers who are sentenced to serve life in
prison without the possibility of parole in California are
never eligible for parole. They spend the rest of their lives
in prison and they die in prison.
5. Fewer than 1% of death row inmates work and pay their
wages to compensate their victims. Murderers sentenced
to life imprisonment without the possibility of parole are
required to work in prison and use their wages to pay
restitution to the victims of their crimes.
6. All convicted murderers sentenced to life imprisonment
without the possibility of parole should be legally required
to work while in prison and pay 60% of their wages to
compensate their victims for the damage they caused.
7. While many think it is cheaper to execute murderers
than to imprison them for life, in fact it is far more
expensive. The death penalty system costs over $100
million more per year to maintain than a system that has
life imprisonment without the possibility of parole as its
harshest punishment, according to a study by former death
penalty prosecutor and judge, Arthur Alarcon, and law
professor Paula Mitchell. By replacing the death penalty
with life imprisonment without the possibility of parole,
California taxpayers would save well over $100 million
every year.
8. The death penalty is a failed government program that
wastes taxpayer dollars and makes fatal mistakes. More
than 150 innocent people have been sentenced to death
in this country, and some innocent people have actually
been executed. Wrongful convictions rob innocent people
of decades of their lives, waste tax dollars, and retraumatize the victims’ families, while the real killers
remain free to kill again.
9. Retroactive application of this act will end a costly and
ineffective practice immediately and ensure that California
never executes an innocent person.
10. California’s death penalty is an empty promise. Death
penalty cases drag on for decades. A sentence of life in
prison without the possibility of parole provides swift and
certain justice for grieving families.
11. Life in prison without the possibility of parole ensures
that the worst criminals stay in prison forever and saves
money. By replacing the death penalty with life in prison
without the possibility of parole, we would save the state
$1 billion in five years without releasing a single
prisoner—$1 billion that could be invested in crime
prevention strategies, services for victims, education, and
keeping our communities and families safe.
SEC. 3. Purpose and Intent.
The people of the State of California declare their purpose
and intent in enacting the act to be as follows:

